$6.76
−1.74%Sep 30, 2026, 12:00 UTC
Eupraxia Pharmaceuticals announced updated 52-week clinical data from the highest dose cohort of its Phase 1b/2a RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis, highlighting long duration of response, high remission rates and tolerability.
Source:Aug 13, 2026, 12:00 UTC
Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis patients, showing reductions in odynophagia and dysphagia severity through 52 weeks post treatment.
Source:Aug 11, 2026, 21:21 UTC
Eupraxia Pharmaceuticals presented new data at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI.
Source:Jul 7, 2026, 12:00 UTC
Eupraxia Pharmaceuticals appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors.
Source: